DBV Technologies - Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 03/31/2024 96,434,369 Total gross of voting rights: 96,434,369 Total net* of voting rights:... Read More

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the year ended December 31, 2023, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its... Read More

DBV Technologies Reports Full Year 2023 Financial Results and Business Update Advanced Viaskin™ Peanut clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old) Strengthened executive leadership team in preparation for BLA submission Reported cash and cash equivalents of $141 million Montrouge, France, March 7, 2024 - DBV Technologies (Euronext: DBV – ISIN:... Read More

Montrouge, France, March 4, 2024 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatments for food allergies, today announced the Company will host a conference call and live audio webcast on Thursday, March 7th, at 5:00 p.m. ET to review full year 2023 financial results and provide a business update. Interested participants may... Read More

Montrouge, France, February 20 2024 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 –NASDAQ: DBVT), a clinical-stage biopharmaceutical company focused on treatments for food allergies, today announced two presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting, February 23-26 in Washington, D.C. A poster presentation by David Fleischer, M.D. of Children’s Hospital Colorado will... Read More

AMF Regulated Information - Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF Montrouge, France, January 16, 2024 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with NATIXIS ODDO BHF. Under the liquidity contract between DBV Technologies and NATIXIS ODDO BHF,... Read More

Viaskin Peanut showed improvement between months 12 and 24 of treatment across all efficacy parameters. Notably, 81.3% of subjects who completed the oral food challenge reached an eliciting dose of ≥1,000 mg after 24 months of treatment. 55.9% of subjects completed the oral food challenge at a cumulative dose of 3,444 mg without meeting stopping criteria. Among treatment-arm subjects from EPITOPE, there were no... Read More

Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 10/31/2023 96,288,553 Total gross of voting rights: 96,288,553 Total net* of voting rights: 96,084,083... Read More

DBV Technologies to Present New Data at ACAAI 2023 New data to include late-breaking abstract detailing interim 12-month results from the ongoing Phase 3 open-label extension to the EPITOPE trial (EPOPEX) of Viaskin™ Peanut in peanut-allergic toddlers. DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that new data on the use of... Read More

DBV has received written feedback from the U.S. Food and Drug Administration (FDA) clarifying design elements for both the COMFORT Toddlers and COMFORT Children supplemental safety studies. Both supplemental safety studies will have harmonized, simplified protocol language on how the product should be used. The COMFORT Toddlers study will apply the same eligibility criteria as EPITOPE, DBV’s successful Phase 3 efficacy study... Read More

Montrouge, France, October 27, 2023 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, October 31 st , at 5:00 p.m. ET to review third quarter 2023 financial results and provide a business update. Interested participants may access this call via the... Read More

Montrouge, France, October 16, 2023 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Virginie Boucinha as its Chief Financial Officer, effective November 6, 2023. An experienced financial and operations executive, Virginie will report directly to Daniel Tassé, Chief Executive Officer, and serve as a member of... Read More

Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 09/30/2023 96,253,553 Total gross of voting rights: 96,253,553 Total net* of voting rights:... Read More

Montrouge, France, September 5, 2023 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the company will participate in the H.C. Wainwright Annual Global Investment Conference taking place on September 11 th −13 th in New York, NY. Daniel Tassé, Chief Executive Officer, will represent the company in a fireside chat session on... Read More

R eceived feedback from U.S. Food and Drug Administration (FDA) on DBV’s two supplemental safety stud ies in toddlers ( ages 1 – 3 years) and children ( ages 4 – 7 years) . The two Phase 3 pivotal safety studies will be named COMFORT Toddlers (1 – 3 years) and COMFORT Children (4 – 7 years). COMFORT Toddlers will be a 6-month safety study, consistent with agreement previously reached with FDA on the COMFORT Children safety... Read More

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Monday, July 31 st , at 5:00 p.m. ET to report first half 2023 financial results and provide a corporate update. Participants may access this event via the below teleconferencing numbers and asking to join the DBV... Read More

Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 06/30/2023 96,250,954 Total gross of voting rights: 96,250,954 Total net* of voting rights: 96,100,982 *... Read More

Montrouge, France, July 10, 2023 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of June 30, 2023: 149,972 DBV Technologies shares, € 317,981.... Read More

Montrouge, France, June 8, 2023 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 9 – 11, 2023, in Hamburg, Germany. DBV will present three posters and will also host a symposium and exhibit booth in the EAACI exhibit hall. Data... Read More

DB V Technologies to Participate in Upcoming Investor Conference Montrouge, France, June 06, 2023 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the Goldman Sachs 44 th Annual Global Healthcare Conference taking place on June 12 th – 15 th in Dana Point, CA. Daniel Tassé, Chief Executive Officer, will engage... Read More

Montrouge, France, May 10, 2023 DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial D ata E valuating Viaskin™ Peanut in Toddlers Th e New England Journal of Medicine (NEJM) published results that demonstrated epicutaneous immunotherapy (EPIT TM ) with Viaskin Peanut was statistically superior to placebo in desensitizing children to peanut by increasing the peanut dose that... Read More

D BV Technologies to Participate in Upcoming Investor Conference Montrouge, France, May 9, 2023 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the JMP Securities Life Sciences Conference taking place May 15-16 in New York, NY. Daniel Tassé, Chief Executive Officer, will make a company presentation on Monday,... Read More

DBV closes Q1 2023 with cash and cash equivalents of $192.3 million . DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported financial results for the first quarter of 2023. The quarterly financial statements were approved by the Board of Directors on May 4, 2023. Financial Highlights for the First Quarter and the Three Months Ended March... Read More

The FDA confirmed that the Company’s Phase 3 EPITOPE study met the pre-specified criteria for success for the primary endpoint and did not request an additional efficacy study . A dditional safety data will be required to augment the safety data collected from EPITOPE in support of a BLA . Th e new safety study will also generate patch adhesion data and include updated Instructions for Use (IFU). Company reports cash and... Read More

DBV Technologies Announces Results of its 202 3 Ordinary and Extraordinary General Meeting Shareholders A pprove d A ll P roposed R esolutions Montrouge, France, April 12, 2023 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today held its Ordinary and Extraordinary General Meeting. The General Meeting was chaired by Michel de Rosen, Chairman of... Read More

Ordinary and Extraordinary General Meeting of April 12, 2023 Procedures for Obtaining Information and Preparatory Documents for the General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, will hold its Ordinary and Extraordinary General Meeting (the “ General Meeting ”) on April 12, 2023, at 10:00 a.m. CET at the Company’s headquarters... Read More

Montrouge, France, March 13, 2023 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), a clinical-stage biopharmaceutical company, informs its investors that it does not hold cash deposits or securities at Silicon Valley Bank. About DBV Technologies DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin... Read More

First patient screened at Midwest Allergy Sinus Asthma in Normal, Illinois VITESSE is DBV’s Phase 3 clinical study evaluating the modified Viaskin Peanut patch in peanut-allergic children ages 4 – 7 years DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the first patient has been screened in the Company’s VITESSE ( V iaskin Peanut I... Read More

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), today announced the filing of its Annual Report on Form 10-K for the year ended December 31, 2022, with the U.S. Securities and Exchange Commission (“SEC”) and the filing of its 2022 Universal Registration Document (“URD”) for the year ended December 31, 2022 with the French market... Read More

DBV completed EVOLVE, a 12-week caregiver and patient user experience study of the modified Viaskin Peanut patch in peanut-allergic children ages 4 – 11 years old DBV had $209.2 million in Cash and Cash Equivalents at December 31, 2022. DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported financial results for the full year 2022. The... Read More

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Thursday, March 2, at 5:00 p.m. ET to report full year 2022 financial results and provide a business update. Interested participants may access this call via the below teleconferencing numbers and asking to join... Read More

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Scientific meeting, taking place February 24-27 in San Antonio, TX. Two scientific poster presentations have been accepted on efficacy and safety data from subgroups of patients from the... Read More

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the virtual SBV Securities Global Biopharma Conference taking place February 13 – 16, 2023. Daniel Tassé, Chief Executive Officer, will make a company presentation on Thursday, February 16, 2023, as well as participate in one-on-one investor meetings throughout... Read More

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologie s (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of December 31, 2022:... Read More

DBV expects to initiate patient screening in Q1 2023 with the last patient screened by 1H 2024 and topline results anticipated in 1H 2025 Company reiterates that cash on-hand is sufficient to fund operations through VITESSE topline data DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA)... Read More